LCLaura Cristoferi

Laura Cristoferi

*This is an algorithmically generated author record based on publicly available information.

Laura Cristoferi has a total of 688 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Letter to the Editor

    by Palak J. Trivedi, Victoria Homer, Johannes R. Hov, Michael Trauner, M. Nabil Quraishi, Benjamin H. Mullish, Gideon M. Hirschfield, Laura Cristoferi, Marco Carbone

    Was not provided for this article.

  • Open Access

    PSC ‐ DM : A Validated Clinical Diagnostic Model for Distinguishing Primary From Secondary Sclerosing Cholangitis

    by Miki Scaravaglio, Rodrigo V. Motta, Laura Cristoferi, Cesare Maino, Alberto Marini, Eugenia Nofit, Eugenia Pesatori, Camilla Gallo, Francesca Bolis, Daphne D'AMato, et al.

    Background and Aims: Primary sclerosing cholangitis (PSC) is a rare, progressive cholangiopathy for which diagnosis remains challenging because of the absence of disease‐specific markers and the presence of secondary causes of sclerosing cholangitis (SSC) that closely mimic its clinical presentation. Diagnostic uncertainty can delay appropriate management and add to the psychological burden experienced by patients. This study aimed to identify clinical parameters that support the early and accurate differentiation of PSC from SSC. Methods: We conducted a multicentre retrospective study of adults with an established diagnosis of PSC or SSC. Independent predictors of PSC were identified using multivariable logistic regression and externally validated in an independent cohort. Results: In the derivation cohort ( n = 234, 155 PSC, 79 SSC), six variables were independently associated with PSC diagnosis, including younger age at presentation ( p < 0.0001), presence of IBD ( p < 0.0001), absence of prior hepato‐pancreato‐biliary surgery ( p < 0.0001), autoimmune comorbidities ( p = 0.0038), family history of autoimmune diseases ( p = 0.0086), and absence of pancreatic abnormalities ( p = 0.0338). These variables were used to develop the PSC diagnostic model (PSC‐DM). In the external validation cohort ( n = 142, 98 PSC, 44 SSC), the AUROC of PSC‐DM was 0.95 (95% CI 0.91–0.98). In an exploratory analysis, PSC‐DM significantly improved non‐expert diagnostic accuracy (94.3% versus 78.6%, p = 0.0023). Conclusions: PSC‐DM is a simple, externally validated clinical prediction model that accurately distinguishes PSC from SSC using routinely available clinical variables. It may support initial diagnostic assessment in non‐specialist settings, facilitate timely referral to expert centres and improve patient selection for clinical trials.

  • Open Access

    Trends in Primary Biliary Cholangitis: Prospective Cohort Study From the European Reference Network Registry (R‐LIVER)

    by A. Gerussi, E. Nofit, D. P. Bernasconi, C. Kroll, F. Groß, I. Schregel, A. Marini, L. Cristoferi, F. Malinverno, M. Papp, et al.

    Background and Aims: The European Reference Network on Hepatological Diseases (ERN RARE‐LIVER) is a Europe‐wide network for centers of excellence in the management of rare liver diseases. We aimed to evaluate the current diagnostic and therapeutic trends of primary biliary cholangitis (PBC). Methods: Prospective data of PBC cases diagnosed from 2017 to March 2024 were extracted from the R‐LIVER registry of ERN‐RARE LIVER. Cases without two follow‐ups within 24 months were excluded from the treatment analysis. Biochemical response according to Toronto criteria and normalization of alkaline phosphatase (ALP) values after 12 months of Ursodeoxycholic Acid (UDCA) were evaluated. Results: This study included 327 incident cases from six centers. Median age was 56 years, 89.3% were female. At the time of diagnosis, median values of ALP were 1.37 x ULN, and median bilirubin was 0.49 x ULN. Transient elastography (TE) was performed in 230 patients (70.3%) at baseline; median liver stiffness was 6.2 kPa. Out of 316 subjects, treatment with UDCA was started in 312 patients (98.7%); 246 (85.1%) achieved ALP values < 1.67 x ULN at 12 months. Normalization of ALP values occurred in 143 subjects (49.5%) at 12 months. Among 43 patients with inadequate response, 18 (41.9%) were treated with second‐line therapies, and had worse liver biochemistry at baseline. Conclusion: In the current era, patients with PBC are diagnosed at an early stage using non‐invasive methods and are almost all treated with UDCA. The biochemical response rate is 85.1%, but the use of second‐line therapies for inadequate responders remains suboptimal.


  • Open Access

    Deep learning helps discriminate between autoimmune hepatitis and primary biliary cholangitis

    by Alessio Gerussi, Oliver Lester Saldanha, Giorgio Cazzaniga, Damiano Verda, Zunamys I. Carrero, Bastian Engel, Richard Taubert, Francesca Bolis, Laura Cristoferi, Federica Malinverno, et al.


  • RESIST criteria accurately rule-out high-risk esophageal varices in patients with primary biliary cholangitis and compensated advanced chronic liver disease

    by Vincenza Calvaruso, Ciro Celsa, Laura Cristoferi, Miki Scaravaglio, Luigi Capodicasa, Luca Cadamuro, Gabriele Di Maria, Vito Di Marco, Alessio Gerussi, Federica Malinverno, et al.

  • Open Access

    LLM-PBC: Logic Learning Machine-Based Explainable Rules Accurately Stratify the Genetic Risk of Primary Biliary Cholangitis

    by Alessio Gerussi, Damiano Verda, Claudio Cappadona, Laura Cristoferi, Davide Paolo Bernasconi, Sandro Bottaro, Marco Carbone, Marco Muselli, Pietro Invernizzi, Rosanna Asselta, et al.

    Background: The application of Machine Learning (ML) to genetic individual-level data represents a foreseeable advancement for the field, which is still in its infancy. Here, we aimed to evaluate the feasibility and accuracy of an ML-based model for disease risk prediction applied to Primary Biliary Cholangitis (PBC). Methods: Genome-wide significant variants identified in subjects of European ancestry in the recently released second international meta-analysis of GWAS in PBC were used as input data. Quality-checked, individual genomic data from two Italian cohorts were used. The ML included the following steps: import of genotype and phenotype data, genetic variant selection, supervised classification of PBC by genotype, generation of “if-then” rules for disease prediction by logic learning machine (LLM), and model validation in a different cohort. Results: The training cohort included 1345 individuals: 444 were PBC cases and 901 were healthy controls. After pre-processing, 41,899 variants entered the analysis. Several configurations of parameters related to feature selection were simulated. The best LLM model reached an Accuracy of 71.7%, a Matthews correlation coefficient of 0.29, a Youden’s value of 0.21, a Sensitivity of 0.28, a Specificity of 0.93, a Positive Predictive Value of 0.66, and a Negative Predictive Value of 0.72. Thirty-eight rules were generated. The rule with the highest covering (19.14) included the following genes: RIN3, KANSL1, TIMMDC1, TNPO3. The validation cohort included 834 individuals: 255 cases and 579 controls. By applying the ruleset derived in the training cohort, the Area under the Curve of the model was 0.73. Conclusions: This study represents the first illustration of an ML model applied to common variants associated with PBC. Our approach is computationally feasible, leverages individual-level data to generate intelligible rules, and can be used for disease prediction in at-risk individuals.


  • Open Access

    Role of ductular reaction and ductular–canalicular junctions in identifying severe primary biliary cholangitis

    by Diletta Overi, Guido Carpino, Laura Cristoferi, Paolo Onori, Lindsey Kennedy, Heather Francis, Nicola Zucchini, Cristina Rigamonti, Mauro Viganò, Annarosa Floreani, et al.


  • Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis

    by Christophe Corpechot, Fabrice Carrat, Farid Gaouar, Frederic Chau, Gideon Hirschfield, Aliya Gulamhusein, Aldo J. Montano-Loza, Ellina Lytvyak, Christoph Schramm, Albert Pares, et al.


  • X marks the spot in autoimmunity

    by Alessio Gerussi, Chiara Caime, Eleonora Binatti, Claudio Cappadona, Laura Cristoferi, Rosanna Asselta, M. Eric Gershwin, Pietro Invernizzi

    Introduction Autoimmune diseases mostly affect females. Besides hormones, several factors related to chromosome X have been called in action to explain this sex predominance. Areas covered This paper provides an overview on the role of chromosome X (chrX) in explaining why females have higher susceptibility to autoimmunity. The work outlines some essential concepts regarding chrX inactivation, escape from chrX inactivation and the evolutionary history of chrX. In addition, we will discuss the concept of gene escape in immune cells, with examples related to specific X-linked genes and autoimmune diseases. Expert opinion There is growing evidence that many genes present on chrX escape inactivation, and some of them have significant immune-mediated functions. In immune cells of female individuals the escape of these genes is not constant, but the knowledge of the mechanisms controlling this plasticity are not completely understood. Future studies aimed at the characterization of these modifications at single-cell resolution, together with conformational 3D studies of the inactive X chromosome, will hopefully help to fill this gap of knowledge.